A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG: CBP-201
DRUG: placebo

Sponsor

Connect Biopharm LLC